



18/c
Goiga
4.24.3
PATENT

Atty. Docket No.: 11111/1220

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, Andrew
Serial No.: 09/345,148
Filed: June 30, 1999
Entitled: CD40 Ligand-enhanced Cells
and Methods of Modulating an
Immune Response

Examiner: Gambel, P

Group Art Unit: 1644

Conf. No.: 9870

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This paper is responsive to the Office Action mailed November 5, 2002. Attached is a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) to extend the period for response one month, up to, and including, April 5, 2003, along with the necessary fee. Please charge any additional fees required in connection with the papers transmitted herewith to Deposit Account No. 16-0085, reference no. 11111/1220. Please enter the following amendments and remarks in the above-captioned patent application.

AMENDMENT

In the Specification

Please replace the specification in its entirety with the substitute specification filed herewith.

In the Claims

Please cancel claim 2, 18, and 69

Please replace claim 17, 23, 28, and 29 with the following claims.

RECEIVED
APR 15 2003
TECH CENTER 1600/2900

C 1 17. (Amended) The method of claim 1 wherein said ligand for CD40 of said CD40 ligand-enhanced cell comprises an exogenous engineered ligand for CD40.